Saying the drug AZT is too expensive for AIDS patients because asingle company holds a monopoly, a Schaumburg company is challengingthe drug's U.S. patent.
Officials for Novopharm Inc., the U.S. arm of Toronto-basedNovopharm Ltd., said it has filed an application with the Food andDrug Administration to provide a generic version of AZT, a medicationthat has been used for AIDS and AIDS-related diseases since 1987.
The drug originally cost more than $10,000 a year for a singlepatient. Since that time, the cost has been lowered twice, to around$2,500 a year.
Novopharm sells a generic AZT drug called Novo-AZT in Canada.But the U.S. market, company officials …
No comments:
Post a Comment